Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MITF | O75030 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL703830 | 1.00 | SMN1; SMN2 (0.85) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL372885 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL372886 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL13732440 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| Potassium Ion SCHEMBL3805984 | 0.89 | SMN1; SMN2 (0.95) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL5082405 | 0.83 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL5082412 | 0.83 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL702722 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL702723 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 | |
| SCHEMBL6152811 | 0.77 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1KDM4ECHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541447-B2 | 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | TARGACEPT, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8158649-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8143272-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8124618-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124620-B2 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124619-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8084462-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110071189-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071187-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| EP-1594869-B9 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT INC (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | ATTENUA, INC. | 2008-06-12 | — | — | US | disclosed |
| EP-1594869-B1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2005-11-17 | — | — | US | disclosed |
| EP-1594869-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | Targacept, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6953855-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| WO-2004076449-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | SCHMITT JEFFREY DANIEL (US) | 2003-03-06 | — | — | US | disclosed |
| US-6432975-B1 | AROMATIC ALKYLENE AZOBICYCLIC COMPOUNDS AS NICOTINIC RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM DISORDER TREATMENT | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071187-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA3, CHRNA5 | SMN1; SMN2 3222/4885ALDH1A1 882/4885KDM4E 1934/4885 |
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | SMN1; SMN2 3054/4885ALDH1A1 880/4885KDM4E 1568/4885 |
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | CHRNG, CHRNB1, CHRNA1 | SMN1; SMN2 2009/4885ALDH1A1 1668/4885KDM4E 1520/4885 |
| US-20110071189-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA3, CHRNA5 | SMN1; SMN2 3222/4885ALDH1A1 882/4885KDM4E 1934/4885 |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | CHRNA7, CHRNA1, CHRNA3 | SMN1; SMN2 3105/4885ALDH1A1 671/4885KDM4E 1572/4885 |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA1 | SMN1; SMN2 3112/4885ALDH1A1 1036/4885KDM4E 1804/4885 |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA5 | SMN1; SMN2 3222/4885ALDH1A1 882/4885KDM4E 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.